All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study

Abstract

Not available.

Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group

“…Ixazomib, an oral proteosome inhibitor, is approved after at least two previous treatment lines in an all-oral triplet with lenalidomide and dexamethasone. A phase 2 IFM study (2013-06) with IRD induction and fixed-length ixazomib maintenance produced over 90% 3-year OS in transplant-eligible patients [ 3 ]. However, they found PFS in that combination to be inferior to VRD + ASCT + lenalidomide maintenance [ 3 ].…”

“…A phase 2 IFM study (2013-06) with IRD induction and fixed-length ixazomib maintenance produced over 90% 3-year OS in transplant-eligible patients [ 3 ]. However, they found PFS in that combination to be inferior to VRD + ASCT + lenalidomide maintenance [ 3 ]. The result of the phase 2 HOVON 143 trial for non-eligible NDMM patients consisting of ixazomib, daratumumab and low-dose dexamethasone was not encouraging, with a median PFS of 18.2 months [ 30 ].…”

“…Ixazomib is approved as a part of an all-oral three-drug regimen (ixazomib–lenalidomide–dexamethasone) for patients with relapsed or refractory myeloma [ 2 ], albeit not in first-line therapy. A phase 2 IFM2013-06 study with 42 patients concluded that induction with IRD followed by autologous stem cell transplantation (ASCT) and IRD consolidation with fixed one-year ixazomib maintenance is safe and effective in NDMM patients with 92.8% 3-year OS [ 3 ]. However, the Spanish Pethema group showed that adding ixazomib as part of a maintenance triplet after ASCT did not prolong PFS, possibly due to reduced ixazomib doses caused by toxicity [ 4 ].…”

The role of maintenance therapy following autologous stem cell transplantation in newly diagnosed multiple myeloma: Considerations on behalf of the Chronic Malignancies Working Party of the EBMT

“…The phase 2 IFM2013‐06 study evaluated IRd induction followed by HDM and AHCT, early and late consolidation and then maintenance with single agent ixazomib 29 . In the intention‐to‐treat group, there was a high ORR of 92.3% with evidence of deepening responses at the end of consolidation when compared to those postinduction.…”

From spear to trident: Upgrading arsenal of CAR-T cells in the treatment of multiple myeloma

“…Apart from the conventional curative approaches reviewed above, some novel agents have been developed, including thalidomide, lenalidomide and bortezomib. Extensive investigations have been carried out surrounding the monotherapy of these three novel agents or exploration of different combination regimens of each other or combinations with conventional agents, for instance, dexamethasone in the RRMM context, namely, triplet or doublet treatment approaches [ 36 ], demonstrating significant response rates and prolonged survival, either alone or in combination in patients with RRMM.…”